Reply:

References

1. 1.↵
   1. Ellingson BM,
   2. Sanvito F,
   3. Cloughesy TF, et al

   . A neuroradiologist’s guide to operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for gliomas in adults. AJNR Am J Neuroradiol 2024;45:1846–56 doi:10.3174/ajnr.A8396 pmid:38926092

   Abstract/FREE Full Text
2. 2.↵
   1. Wen PY,
   2. Van Den Bent MJ,
   3. Youssef G, et al

   . RANO 2.0: Update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 2023;41:5187–99 doi:10.1200/JCO.23.01059 pmid:37774317

   CrossRefPubMed
3. 3.↵
   1. Sanvito F,
   2. Castellano A,
   3. Cloughesy TF, et al

   . RANO 2.0 criteria: concepts applicable to the neuroradiologist’s clinical practice. Curr Opin Oncol doi:10.1097/CCO.0000000000001077 pmid:39011735

   CrossRefPubMed
4. 4.↵
   1. Youssef G,
   2. Rahman R,
   3. Bay C, et al

   . Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:3160–71 doi:10.1200/JCO.22.01579 pmid:37027809

   CrossRefPubMed
5. 5.↵
   1. Weinberg BD,
   2. Gore A,
   3. Shu H-KG, et al

   . Management-based structured reporting of posttreatment glioma response with the Brain Tumor Reporting and Data System. J Am Coll Radiol 2018;15:767–71 doi:10.1016/j.jacr.2018.01.022 pmid:29503151

   CrossRefPubMed
6. 6.↵
   1. Ellingson BM,
   2. Wen PY,
   3. Chang SM, et al

   . Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro Oncol 2023;25:1017–28 doi:10.1093/neuonc/noad002 pmid:36617262

   CrossRefPubMed
7. 7.↵
   1. Okada H,
   2. Weller M,
   3. Huang R, et al

   . Immunotherapy response assessment in neuro-oncology: a report of the RANO Working Group. Lancet Oncol 2015;16:e534–42 doi:10.1016/S1470-2045(15)00088-1 pmid:26545842

   CrossRefPubMed
8. 8.↵
   1. van den Bent MJ,
   2. Wefel JS,
   3. Schiff D, et al

   . Response Assessment in Neuro-Oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583–93 doi:10.1016/S1470-2045(11)70057-2 pmid:21474379

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Wen PY,
   2. Macdonald DR,
   3. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text